<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868972</url>
  </required_header>
  <id_info>
    <org_study_id>MOMPF-01</org_study_id>
    <nct_id>NCT00868972</nct_id>
  </id_info>
  <brief_title>Renal Stenting With Distal Atheroembolic Protection</brief_title>
  <official_title>Percutaneous Renal Stenting in Renovascular Disease With or Without Distal Atheroembolic Protection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universita di Verona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universita di Verona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atherosclerotic renal artery stenosis (ARAS) is associated with progressive loss of renal&#xD;
      function, refractory hypertension and flushing edema, responsible for mortality and&#xD;
      morbidity, especially in the elderly. Current treatment includes restoration of the renal&#xD;
      arterial lumen by endovascular stent placement and/or intensive medical therapy. There is no&#xD;
      unanimous consent on which patients could benefice of the endovascular procedure due to the&#xD;
      high rate of renal adverse events especially linked to atheroembolic disease. Recently, renal&#xD;
      revascularization using a device which consents distal embolic protection of the kidney&#xD;
      demonstrated to be a &quot;safe&quot; auxiliary procedure in a few non randomized studies.&#xD;
      Interestingly atheromatous debris was detected in 60 to 80% of these devices analyzed after&#xD;
      the procedure suggesting that these devices could prevent atheroembolism in a substantial&#xD;
      proportion of patients. On the other hand, only a randomized controlled study can prove that&#xD;
      renal stent with distal embolic protection is superior to renal stent alone in preserving&#xD;
      kidney function.&#xD;
&#xD;
      Therefore, the present study aims to compare the effects of renal artery stent placement with&#xD;
      or without distal embolic protection on renal function in ARAS patients.&#xD;
&#xD;
      Method:&#xD;
&#xD;
      Patients with an ARAS of ≥70% and hypertension not responsive to at least 2 antihypertensive&#xD;
      medications and/or renal failure (estimated GFR &lt;60 mL/min/1.73 m2 are randomly assigned to&#xD;
      stent placement alone or stent placement with distal embolic protection (FILTER WIRE EX;&#xD;
      Cordis Endovascular, USA).&#xD;
&#xD;
      Other medications consist of statins, anti-hypertensive drugs and antiplatelet therapy.&#xD;
      Patients are followed for 3 months. The primary outcome of this study is a statistical&#xD;
      significant difference in kidney function measured as Cr clearance and cystatin C level in&#xD;
      the 2 groups at three months. The trial will include 150 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized trial of patients with an ostial ARAS and refractory hypertension and or&#xD;
      renal failure. Patients will be randomized to:&#xD;
&#xD;
      (i) renal artery stent placement with distal embolic protection (ii) renal artery stent&#xD;
      placement without distal embolic protection To both groups an optimal medical treatment&#xD;
      consisting of antihypertensive, lipid-lowering and antiplatelet therapy will be added.&#xD;
&#xD;
      Patients with an ostial ARAS associated with an estimated GFR of &lt;60 mL/min/1.73m2 according&#xD;
      to the MDRD formula and/or refractory hypertension are enrolled in this trial. Ostial ARAS is&#xD;
      defined as a luminal reduction of ≥70% of the renal artery within 1 cm of the aortic wall, in&#xD;
      the presence of atherosclerotic changes of the aorta. Stenosis evaluation can be performed on&#xD;
      intra-arterial angiography.&#xD;
&#xD;
      Medical therapy: Irrespective of baseline serum cholesterol values, the patients will be&#xD;
      treated with lipid-lowering therapy: 10 mg of rosuvastatin. Any lipid-lowering medication&#xD;
      currently used is discontinued and replaced by rosuvastatin. Hypertension is treated with the&#xD;
      following drugs: ACE-inhibitors together, loop diuretic, dihydropyridine calcium antagonists.&#xD;
      The target BP is &lt;140/90 mmHg. Patients will receive anti-platelet therapy, aspirin 75-100&#xD;
      mg/od plus ticlopidine 250 mg bid for one month. Considering that smoking is a major renal&#xD;
      risk factor, smokers will be advised to stop.&#xD;
&#xD;
      Medical therapy is identical in the two treatment arms. In both groups patients will start&#xD;
      with aspirin 100 mg/od and ticlopidine 250 mg bid at least five days before admission. The&#xD;
      stent (Palmaz-Corinthian IQ/Palmaz Genesis, Johnson &amp; Johnson Medical, NV/SA) will be placed&#xD;
      during an in-patient admission according to a standardized protocol. To Patients randomized&#xD;
      to the embolic protection the device (FILTER WIRE EX; Cordis Endovascular, USA) will be&#xD;
      placed distal to the arterial stenosis before stent placement.&#xD;
&#xD;
      Randomization will be done using random numbers tables The only people aware of the assigned&#xD;
      procedure will be the radiologists' team. Researchers and technicians who will follow the&#xD;
      patients and analyze the plasma and urinary samples will be blinded to the assigned&#xD;
      treatment.&#xD;
&#xD;
      Clinical follow-up is scheduled after 1 and 3 months. Analysis of results: The difference in&#xD;
      the mean change of cystatin C respect to baseline between both treatment arms will be&#xD;
      assessed including 95% confidence intervals (95% CI). The effects on renal function of the&#xD;
      two treatment strategies will be evaluated with multivariate linear regression analysis,&#xD;
      considering also the eventual role of age, smoking, diabetes, lipids level, proteinuria,&#xD;
      bilateral or unilateral renal artery stenosis, BP and renal function at baseline&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in renal function loss (measured as Cr clearance and/or cystatin C) after 1 and 3 months of follow-up</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute complications, especially atheroembolism</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluations of the covariates associated with a better outcome in the atheroembolic device group</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure control (number of medication needed to keep BP&lt;140/90 )</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Renal Artery Obstruction</condition>
  <condition>Renovascular Hypertension</condition>
  <arm_group>
    <arm_group_label>Embolic protection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous renal stenting using a distal embolic protection device (filter wire ex; Cordis Endovascular, USA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No embolic protection</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Percutaneous renal stenting intervention without embolic protection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous renal stenting intervention</intervention_name>
    <description>Percutaneous renal stenting intervention</description>
    <arm_group_label>Embolic protection</arm_group_label>
    <arm_group_label>No embolic protection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Distal embolic protection</intervention_name>
    <description>Distal embolic protection device (filter wire ex; Cordis Endovascular, USA).</description>
    <arm_group_label>Embolic protection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Ostial atherosclerotic renal artery stenosis ≥70% on intra-arterial angiography&#xD;
&#xD;
          -  Well documented history of hypertension (&gt;140/90 mmHg) non responsive to the use of 2&#xD;
             or more antihypertensive medications and/or&#xD;
&#xD;
          -  Estimated glomerular filtration rate &lt;60 ml/min/1.73m2 according to the MDRD formula,&#xD;
             on two occasions within one month&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Declined informed consent&#xD;
&#xD;
          -  Renal longitudinal diameter &lt; 8 cm&#xD;
&#xD;
          -  Any anatomical reasons that make impossible the PTRA and or the positioning of the&#xD;
             distal embolic protection device&#xD;
&#xD;
          -  Estimated glomerular filtration rate &lt;30 ml/min/1.73m2 according to the MDRD formula&#xD;
             or on dialysis&#xD;
&#xD;
          -  Allergy to the contrast medium used during angiography&#xD;
&#xD;
          -  Other conditions associated with (within 6 months) poor prognosis&#xD;
&#xD;
          -  Myocardial infarction, unstable angina or stroke &lt;1 month before planned date of&#xD;
             inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giancarlo Mansueto, MD, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univerista di Verona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giancarlo Mansueto, MD, professor</last_name>
    <phone>00390458124301</phone>
    <email>giancarlo.mansueto@univr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oliviero Olivieri, MD, professor</last_name>
    <phone>00390454627</phone>
    <email>oliviero.olivieri@univr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Verona, Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giancarlo Mansueto, MD, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>March 24, 2009</study_first_submitted>
  <study_first_submitted_qc>March 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2009</study_first_posted>
  <last_update_submitted>January 22, 2010</last_update_submitted>
  <last_update_submitted_qc>January 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Giancarlo Mansueto</name_title>
    <organization>Università di Verona</organization>
  </responsible_party>
  <keyword>Renal Artery Obstruction</keyword>
  <keyword>renovascular hypertension</keyword>
  <keyword>stent</keyword>
  <keyword>Kidney Failure</keyword>
  <keyword>embolic protection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Artery Obstruction</mesh_term>
    <mesh_term>Hypertension, Renovascular</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

